The bio-pharmaceutical company, which sells its products across China as well as to selected developing countries, raised $123.2 million ahead of its Nasdaq trading debut yesterday, tapping into the strong demand for healthcare investments by US funds in particular.
UBS was sole bookrunner for the offering, while CIBC World Markets and Pacific Growth Equities were also part of the underwriting syndicate.
3SBio focuses on genetically-engineered, protein-based products targeted at the areas of nephrology, oncology, supportive cancer care, inflammation and infectious diseases. It has a...
¬ Haymarket Media Limited. All rights reserved.
